Literature DB >> 7878047

A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.

D Lévesque1, M P Martres, J Diaz, N Griffon, C H Lammers, P Sokoloff, J C Schwartz.   

Abstract

The effects of interruption of dopaminergic transmission or sustained blockade of dopamine receptors by neuroleptics on the dopamine D3 receptor in the shell of the nucleus accumbens were investigated in rats. In this brain area the D3 receptor is abundant and may mediate antipsychotic drug effects. The D3 receptor density and mRNA abundance were evaluated with 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin and by quantitative PCR or image analysis of in situ hybridization signals, respectively. Unilateral dopamine neuron degeneration by 6-hydroxydopamine or sections triggered, after a few days, a marked decrease (up to 50%) in D3 receptor binding and mRNA in the nucleus accumbens. In contrast, a 2-week treatment with the neuroleptic haloperidol (20 mg/kg) had no effect on D3 receptor density and mRNA but enhanced D2 receptor density and mRNA level by > 50%. In addition, tolerance to the haloperidol-induced change of neurotensin mRNA mediated by the D2 receptor developed, but there was no tolerance to the opposite change mediated by the D3 receptor. Reserpine, a monoamine-depleting drug with antipsychotic activity, did not modify D3 receptor mRNA. These observations reinforce the idea that the D3 receptor may be an important target for neuroleptics whose antipsychotic actions, but not extrapyramidal motor actions, do not display tolerance. The D3 receptor mRNA level was also decreased by a unilateral injection in dopamine cell body areas of colchicine, a drug blocking the anterograde axonal transport, or by baclofen, a type A gamma-aminobutyric acid receptor agonist reducing dopamine neuron activity, but not by sustained blockade of D1-like and D2-like, neurotensin, or cholecystokinin receptors. We therefore propose that an anterograde factor present in mesolimbic dopaminergic neurons, but distinct from dopamine and known peptide cotransmitters, plays a positive role on transcription of the D3 receptor gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7878047      PMCID: PMC42591          DOI: 10.1073/pnas.92.5.1719

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment.

Authors:  P R Buckland; M C O'Donovan; P McGuffin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effect of raclopride on dopamine D2 receptor mRNA expression in rat brain.

Authors:  J Kopp; N Lindefors; S Brené; H Hall; H Persson; G Sedvall
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

3.  A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques.

Authors:  A Mansour; J H Meador-Woodruff; Q Zhou; O Civelli; H Akil; S J Watson
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

4.  Cloning and functional characterization of a cocaine-sensitive dopamine transporter.

Authors:  B Giros; S el Mestikawy; L Bertrand; M G Caron
Journal:  FEBS Lett       Date:  1991-12-16       Impact factor: 4.124

5.  Effects of dopaminergic transmission interruption on the D2 receptor isoforms in various cerebral tissues.

Authors:  M P Martres; P Sokoloff; B Giros; J C Schwartz
Journal:  J Neurochem       Date:  1992-02       Impact factor: 5.372

6.  Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

Authors:  R S Chang; V J Lotti
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.

Authors:  P Sokoloff; M Andrieux; R Besançon; C Pilon; M P Martres; B Giros; J C Schwartz
Journal:  Eur J Pharmacol       Date:  1992-04-10       Impact factor: 4.432

8.  Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin.

Authors:  D Lévesque; J Diaz; C Pilon; M P Martres; B Giros; E Souil; D Schott; J L Morgat; J C Schwartz; P Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

9.  Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.

Authors:  M L Bouthenet; E Souil; M P Martres; P Sokoloff; B Giros; J C Schwartz
Journal:  Brain Res       Date:  1991-11-15       Impact factor: 3.252

10.  Calcitonin gene-related peptide and muscle activity regulate acetylcholine receptor alpha-subunit mRNA levels by distinct intracellular pathways.

Authors:  B Fontaine; A Klarsfeld; J P Changeux
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539

View more
  25 in total

1.  Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders.

Authors:  Pierre Sokoloff; Olivier Guillin; Jorge Diaz; Patrick Carroll; Nathalie Griffon
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

2.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

3.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

4.  Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Authors:  Isabelle Boileau; Doris Payer; Pablo M Rusjan; Sylvain Houle; Junchao Tong; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2016-06-29       Impact factor: 7.853

5.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

6.  Selective expression of dopamine D3 receptor mRNA in proliferative zones during embryonic development of the rat brain.

Authors:  J Diaz; S Ridray; V Mignon; N Griffon; J C Schwartz; P Sokoloff
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

7.  Absorbed radiation dosimetry of the D3-specific PET radioligand [18F]FluorTriopride estimated using rodent and nonhuman primate.

Authors:  Richard Laforest; Morvarid Karimi; Stephen M Moerlein; Jinbin Xu; Hubert P Flores; Christopher Bognar; Aixiao Li; Robert H Mach; Joel S Perlmutter; Zhude Tu
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-11-30

8.  Dopamine D3 receptors expressed by all mesencephalic dopamine neurons.

Authors:  J Diaz; C Pilon; B Le Foll; C Gros; A Triller; J C Schwartz; P Sokoloff
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

9.  Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.

Authors:  Elissa M Strome; Athanasios P Zis; Doris J Doudet
Journal:  J Psychiatry Neurosci       Date:  2007-05       Impact factor: 6.186

10.  Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Erik H F Wong; Brian Henry; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2008-02-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.